The DOI matches its Crossref record; 221 of the 221 references it cites were found in a registry or an index.
Therapeutic strategies for Parkinson disease: beyond dopaminergic drugs
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Items 201–221 of 221
Morin, N., & Paolo, T. D. (2014) · Frontiers in Neurology · doi:10.3389/fneur.2014.00144 · Cited by 37
Non-human primate models of PD to test novel therapies
Morissette, M., & Paolo, T. D. (2017) · Journal of Neural Transmission · doi:10.1007/s00702-017-1722-y · Cited by 37
Glucocerebrosidase in Parkinson's disease: Insights into pathogenesis and prospects for treatment
Schapira, A. H. V., Chiasserini, D., Beccari, T., & Parnetti, L. (2016) · Movement Disorders · doi:10.1002/mds.26616 · Cited by 35
Safety and tolerability of MRI-guided infusion of AAV2-hAADC into the mid-brain of nonhuman primate
Sebastián, W. S., Kells, A. P., Bringas, J., Samaranch, L., Hadaczek, P., Ciesielska, A., Macayan, M., Pivirotto, P., Forsayeth, J., Osborne, S., et al. (2014) · Molecular Therapy — Methods & Clinical Development · doi:10.1038/mtm.2014.49 · Cited by 34
mGlu4 allosteric modulation for treating Parkinson's disease
Charvin, D. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.03.027 · Cited by 33
Self-citationPeripheral Biomarkers of Parkinson’s Disease Progression and Pioglitazone Effects
Simon, D. K., On behalf of the NINDS NET-PD Investigators, Simuni, T., Elm, J. J., Clark, J., Graebner, A. K., Baker, L., Dunlop, S. R., Emborg, M. E., Kamp, C., et al. (2015) · Journal of Parkinson s Disease · doi:10.3233/jpd-150666 · Cited by 31
Stewart, H. J., Ralph, G. S., Fong-Wong, L., Strickland, I. T., McCloskey, L., Barnes, L., Blount, I., Wells, O. S., Truran, C. J. M., Kingsman, A. J., et al. (2016) · Human Gene Therapy Clinical Development · doi:10.1089/humc.2016.056 · Cited by 31
Targeting α‐Synuclein as a therapy for Parkinson's disease: The battle begins
Olanow, C. W., & Kordower, J. H. (2017) · Movement Disorders · doi:10.1002/mds.26935 · Cited by 31
Glutamatergic mechanisms in l-DOPA-induced dyskinesia and therapeutic implications
Mellone, M., & Gardoni, F. (2018) · Journal of Neural Transmission · doi:10.1007/s00702-018-1846-8 · Cited by 30
Zesiewicz, T. A., Sullivan, K. L., Freeman, A. A. H., & Juncos, J. L. (2008) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.2008.01070.x · Cited by 29
Novel levodopa formulations in the treatment of Parkinson's disease
Pilleri, M., & Antonini, A. (2014) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2014.877840 · Cited by 29
Perspective on the Road toward Gene Therapy for Parkinson’s Disease
Blits, B., & Petry, H. (2017) · Frontiers in Neuroanatomy · doi:10.3389/fnana.2016.00128 · Cited by 29
Izurieta, P., Sarre, S., Ebinger, G., & Michotte, Y. M. (1998) · European Journal of Pharmacology · doi:10.1016/s0014-2999(98)00393-8 · Cited by 25
Clinical trials aimed at detecting neuroprotection in Parkinson’s disease
Hauser, R. A., & Zesiewicz, T. (2006) · Neurology · doi:10.1212/wnl.66.10_suppl_4.s58 · Cited by 20
Self-citationDoes amantadine induce acute psychosis? A case report and literature review
Xu, W., Ning, W., Xu, Y., & Hu, S. (2016) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s101569 · Cited by 20
Hubbard, D. T., Hacksell, U., & McFarland, K. (2013) · Behavioural Pharmacology · doi:10.1097/fbp.0b013e3283656db6 · Cited by 18
Bryś, M., Ellenbogen, A. L., Fanning, L., Penner, N., Yang, M., Welch, M., Koenig, E., David, E., Fox, T., Makh, S., et al. (2018) · Neurology · doi:10.1212/wnl.90.15_supplement.s26.001 · Cited by 17
Advances in clinical trials for movement disorders
Kieburtz, K. D., & Olanow, C. W. (2015) · Movement Disorders · doi:10.1002/mds.26371 · Cited by 13
Glucagon‐like Peptides (GLP‐1) Perspectives in Synucleinopathies Treatment
Foltynie, T., & Athauda, D. S. (2018) · Movement Disorders Clinical Practice · doi:10.1002/mdc3.12611 · Cited by 8
Metabotropic Glutamate Receptors and Parkinson’s Disease: Basic and Preclinical Neuroscience
Gubellini, P., Iskhakova, L., Smith, Y., & Amalric, M. (2017) · Springer eBooks · doi:10.1007/978-3-319-56170-7_3 · Cited by 5
Glutamate Receptors and Levodopa-Induced Dyskinesia
Picconi, B., & Calabresi, P. (2014) · Springer eBooks · doi:10.1007/978-1-4471-6503-3_13 · Cited by 3
Cited by
Balestrino, R., & Schapira, A. H. V. (2020) · European Journal of Neurology · doi:10.1111/ene.14108 · Cited by 1,508
In vitro Models of Neurodegenerative Diseases
Slanzi, A., Iannoto, G., Rossi, B., Zenaro, E., & Constantin, G. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00328 · Cited by 290
Microglia-targeting nanotherapeutics for neurodegenerative diseases
Zhao, N., Francis, N. L., Calvelli, H. R., & Moghe, P. V. (2020) · APL Bioengineering · doi:10.1063/5.0013178 · Cited by 104
Xue, C., Li, X., Ba, L., Zhang, M., Yang, Y., Gao, Y., Sun, Z., Han, Q., & Zhao, R. C. (2021) · Aging and disease · doi:10.14336/ad.2020.1221 · Cited by 100
Lee, E. J., Choi, Y., Lee, H. J., Hwang, D. W., & Lee, D. S. (2022) · Journal of Nanobiotechnology · doi:10.1186/s12951-022-01356-2 · Cited by 89
Metadata
- Authors
- Charvin, D., Medori, R., Hauser, R. A., & Rascol, O.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2018-09-28
- Volume
- 17
- Issue
- 11
- Pages
- 804-822
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2894229433
- Cited by
- 287
- References
- 221
- FWCI
- 6.36
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.